Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Identifieur interne : 001178 ( PubMed/Corpus ); précédent : 001177; suivant : 001179Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Auteurs : Carlos Solano ; Monica Slavin ; Alissa J. Shaul ; David I. Marks ; Catherine Cordonnier ; Oliver A. Cornely ; Antonio Pagliuca ; Lael Cragin ; Isidro Jarque ; Carolina Garcia-Vidal ; Sonja Sorensen ; David J. Vanness ; Claudie Charbonneau ; Jon Andoni Barrueta ; Carmen Peral ; Marina De Salas-Cansado ; Eric J. BowSource :
- Mycoses [ 1439-0507 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Antifungal Agents (economics), Antifungal Agents (therapeutic use), Cost-Benefit Analysis, Decision Support Techniques, Fluconazole (economics), Fluconazole (therapeutic use), Hematopoietic Stem Cell Transplantation, Humans, Invasive Fungal Infections (economics), Invasive Fungal Infections (ethnology), Invasive Fungal Infections (microbiology), Invasive Fungal Infections (prevention & control), Itraconazole (economics), Itraconazole (therapeutic use), Spain, Triazoles (economics), Triazoles (therapeutic use), Voriconazole (therapeutic use).
- MESH :
- chemical , economics : Antifungal Agents, Fluconazole, Itraconazole, Triazoles.
- chemical , therapeutic use : Antifungal Agents, Fluconazole, Itraconazole, Triazoles, Voriconazole.
- economics : Invasive Fungal Infections.
- ethnology : Invasive Fungal Infections.
- microbiology : Invasive Fungal Infections.
- prevention & control : Invasive Fungal Infections.
- Adult, Cost-Benefit Analysis, Decision Support Techniques, Hematopoietic Stem Cell Transplantation, Humans, Spain.
Abstract
Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. Generic itraconazole was the least costly AFP (€162) relative to fluconazole (€500), posaconazole oral suspension (€8628) or voriconazole (€6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough IFIs (36 vs 60); thus, the model predicted fewer deaths from breakthrough IFI for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with other licensed antifungal treatment and IFI treatment in a cohort of 1000. Voriconazole resulted in cost savings of €4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost-effective. As primary AFP in alloHSCT patients 180 days posttransplant, voriconazole was more likely to be cost-effective than posaconazole regarding cost per additional IFI and additional death avoided.
DOI: 10.1111/myc.12552
PubMed: 27562016
Links to Exploration step
pubmed:27562016Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.</title><author><name sortKey="Solano, Carlos" sort="Solano, Carlos" uniqKey="Solano C" first="Carlos" last="Solano">Carlos Solano</name><affiliation><nlm:affiliation>Hospital Clínico, INCLIVA-University of Valencia, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name><affiliation><nlm:affiliation>Royal Melbourne Hospital, Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Shaul, Alissa J" sort="Shaul, Alissa J" uniqKey="Shaul A" first="Alissa J" last="Shaul">Alissa J. Shaul</name><affiliation><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marks, David I" sort="Marks, David I" uniqKey="Marks D" first="David I" last="Marks">David I. Marks</name><affiliation><nlm:affiliation>University Hospitals Bristol NHS Foundation Trust, Bristol, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Cordonnier, Catherine" sort="Cordonnier, Catherine" uniqKey="Cordonnier C" first="Catherine" last="Cordonnier">Catherine Cordonnier</name><affiliation><nlm:affiliation>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name><affiliation><nlm:affiliation>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pagliuca, Antonio" sort="Pagliuca, Antonio" uniqKey="Pagliuca A" first="Antonio" last="Pagliuca">Antonio Pagliuca</name><affiliation><nlm:affiliation>King's College Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Cragin, Lael" sort="Cragin, Lael" uniqKey="Cragin L" first="Lael" last="Cragin">Lael Cragin</name><affiliation><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jarque, Isidro" sort="Jarque, Isidro" uniqKey="Jarque I" first="Isidro" last="Jarque">Isidro Jarque</name><affiliation><nlm:affiliation>Hospital Universitari i Politècnic La Fe, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name><affiliation><nlm:affiliation>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Sorensen, Sonja" sort="Sorensen, Sonja" uniqKey="Sorensen S" first="Sonja" last="Sorensen">Sonja Sorensen</name><affiliation><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Vanness, David J" sort="Vanness, David J" uniqKey="Vanness D" first="David J" last="Vanness">David J. Vanness</name><affiliation><nlm:affiliation>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation><nlm:affiliation>Pfizer Inc, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Barrueta, Jon Andoni" sort="Barrueta, Jon Andoni" uniqKey="Barrueta J" first="Jon Andoni" last="Barrueta">Jon Andoni Barrueta</name><affiliation><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Peral, Carmen" sort="Peral, Carmen" uniqKey="Peral C" first="Carmen" last="Peral">Carmen Peral</name><affiliation><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="De Salas Cansado, Marina" sort="De Salas Cansado, Marina" uniqKey="De Salas Cansado M" first="Marina" last="De Salas-Cansado">Marina De Salas-Cansado</name><affiliation><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Bow, Eric J" sort="Bow, Eric J" uniqKey="Bow E" first="Eric J" last="Bow">Eric J. Bow</name><affiliation><nlm:affiliation>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27562016</idno><idno type="pmid">27562016</idno><idno type="doi">10.1111/myc.12552</idno><idno type="wicri:Area/PubMed/Corpus">001178</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001178</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.</title><author><name sortKey="Solano, Carlos" sort="Solano, Carlos" uniqKey="Solano C" first="Carlos" last="Solano">Carlos Solano</name><affiliation><nlm:affiliation>Hospital Clínico, INCLIVA-University of Valencia, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name><affiliation><nlm:affiliation>Royal Melbourne Hospital, Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Shaul, Alissa J" sort="Shaul, Alissa J" uniqKey="Shaul A" first="Alissa J" last="Shaul">Alissa J. Shaul</name><affiliation><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marks, David I" sort="Marks, David I" uniqKey="Marks D" first="David I" last="Marks">David I. Marks</name><affiliation><nlm:affiliation>University Hospitals Bristol NHS Foundation Trust, Bristol, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Cordonnier, Catherine" sort="Cordonnier, Catherine" uniqKey="Cordonnier C" first="Catherine" last="Cordonnier">Catherine Cordonnier</name><affiliation><nlm:affiliation>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name><affiliation><nlm:affiliation>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pagliuca, Antonio" sort="Pagliuca, Antonio" uniqKey="Pagliuca A" first="Antonio" last="Pagliuca">Antonio Pagliuca</name><affiliation><nlm:affiliation>King's College Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Cragin, Lael" sort="Cragin, Lael" uniqKey="Cragin L" first="Lael" last="Cragin">Lael Cragin</name><affiliation><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jarque, Isidro" sort="Jarque, Isidro" uniqKey="Jarque I" first="Isidro" last="Jarque">Isidro Jarque</name><affiliation><nlm:affiliation>Hospital Universitari i Politècnic La Fe, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name><affiliation><nlm:affiliation>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Sorensen, Sonja" sort="Sorensen, Sonja" uniqKey="Sorensen S" first="Sonja" last="Sorensen">Sonja Sorensen</name><affiliation><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Vanness, David J" sort="Vanness, David J" uniqKey="Vanness D" first="David J" last="Vanness">David J. Vanness</name><affiliation><nlm:affiliation>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation><nlm:affiliation>Pfizer Inc, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Barrueta, Jon Andoni" sort="Barrueta, Jon Andoni" uniqKey="Barrueta J" first="Jon Andoni" last="Barrueta">Jon Andoni Barrueta</name><affiliation><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Peral, Carmen" sort="Peral, Carmen" uniqKey="Peral C" first="Carmen" last="Peral">Carmen Peral</name><affiliation><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="De Salas Cansado, Marina" sort="De Salas Cansado, Marina" uniqKey="De Salas Cansado M" first="Marina" last="De Salas-Cansado">Marina De Salas-Cansado</name><affiliation><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Bow, Eric J" sort="Bow, Eric J" uniqKey="Bow E" first="Eric J" last="Bow">Eric J. Bow</name><affiliation><nlm:affiliation>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Mycoses</title><idno type="eISSN">1439-0507</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antifungal Agents (economics)</term><term>Antifungal Agents (therapeutic use)</term><term>Cost-Benefit Analysis</term><term>Decision Support Techniques</term><term>Fluconazole (economics)</term><term>Fluconazole (therapeutic use)</term><term>Hematopoietic Stem Cell Transplantation</term><term>Humans</term><term>Invasive Fungal Infections (economics)</term><term>Invasive Fungal Infections (ethnology)</term><term>Invasive Fungal Infections (microbiology)</term><term>Invasive Fungal Infections (prevention & control)</term><term>Itraconazole (economics)</term><term>Itraconazole (therapeutic use)</term><term>Spain</term><term>Triazoles (economics)</term><term>Triazoles (therapeutic use)</term><term>Voriconazole (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antifungal Agents</term><term>Fluconazole</term><term>Itraconazole</term><term>Triazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antifungal Agents</term><term>Fluconazole</term><term>Itraconazole</term><term>Triazoles</term><term>Voriconazole</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" qualifier="ethnology" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cost-Benefit Analysis</term><term>Decision Support Techniques</term><term>Hematopoietic Stem Cell Transplantation</term><term>Humans</term><term>Spain</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. Generic itraconazole was the least costly AFP (€162) relative to fluconazole (€500), posaconazole oral suspension (€8628) or voriconazole (€6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough IFIs (36 vs 60); thus, the model predicted fewer deaths from breakthrough IFI for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with other licensed antifungal treatment and IFI treatment in a cohort of 1000. Voriconazole resulted in cost savings of €4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost-effective. As primary AFP in alloHSCT patients 180 days posttransplant, voriconazole was more likely to be cost-effective than posaconazole regarding cost per additional IFI and additional death avoided.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27562016</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>26</Day></DateCreated><DateCompleted><Year>2017</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0507</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Mycoses</Title><ISOAbbreviation>Mycoses</ISOAbbreviation></Journal><ArticleTitle>Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.</ArticleTitle><Pagination><MedlinePgn>79-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/myc.12552</ELocationID><Abstract><AbstractText>Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. Generic itraconazole was the least costly AFP (€162) relative to fluconazole (€500), posaconazole oral suspension (€8628) or voriconazole (€6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough IFIs (36 vs 60); thus, the model predicted fewer deaths from breakthrough IFI for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with other licensed antifungal treatment and IFI treatment in a cohort of 1000. Voriconazole resulted in cost savings of €4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost-effective. As primary AFP in alloHSCT patients 180 days posttransplant, voriconazole was more likely to be cost-effective than posaconazole regarding cost per additional IFI and additional death avoided.</AbstractText><CopyrightInformation>© 2016 The Authors. Mycoses Published by Blackwell Verlag GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Solano</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-3702-0817</Identifier><AffiliationInfo><Affiliation>Hospital Clínico, INCLIVA-University of Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slavin</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Royal Melbourne Hospital, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaul</LastName><ForeName>Alissa J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>David I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>University Hospitals Bristol NHS Foundation Trust, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordonnier</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornely</LastName><ForeName>Oliver A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagliuca</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cragin</LastName><ForeName>Lael</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarque</LastName><ForeName>Isidro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hospital Universitari i Politècnic La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Vidal</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Sonja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanness</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbonneau</LastName><ForeName>Claudie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrueta</LastName><ForeName>Jon Andoni</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peral</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Salas-Cansado</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bow</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Studies</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Mycoses</MedlineTA><NlmUniqueID>8805008</NlmUniqueID><ISSNLinking>0933-7407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>304NUG5GF4</RegistryNumber><NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>6TK1G07BHZ</RegistryNumber><NameOfSubstance UI="C101425">posaconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>8VZV102JFY</RegistryNumber><NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>JFU09I87TR</RegistryNumber><NameOfSubstance UI="D065819">Voriconazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015725" MajorTopicYN="N">Fluconazole</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072742" MajorTopicYN="N">Invasive Fungal Infections</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065819" MajorTopicYN="N">Voriconazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antifungal prophylaxis</Keyword><Keyword MajorTopicYN="Y">azoles</Keyword><Keyword MajorTopicYN="Y">cost-effectiveness</Keyword><Keyword MajorTopicYN="Y">invasive fungal infections</Keyword><Keyword MajorTopicYN="Y">pharmacoeconomics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27562016</ArticleId><ArticleId IdType="doi">10.1111/myc.12552</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001178 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001178 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27562016
|texte= Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27562016" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |